Image pharmaphorum Editor Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars? Debates & Insight Sponsored Powering pharma’s commercial teams with market access insigh... Debates & Insight Sponsored Powering the life sciences commercial engine with market acc... Views & Analysis Clinical trials: realising the untapped potential Winning proposal to create a corporate social responsibility (CSR) programme. Load more results
Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars?
Views & Analysis Clinical trials: realising the untapped potential Winning proposal to create a corporate social responsibility (CSR) programme.
News Roche culls myostatin candidate from obesity pipeline Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
